Comment in The Lancet

In this week’s issue of the Lancet, Brian Greenwood from the London School of Hygiene and Tropical Medicine comments on the recent WHO Report on Placebo Use in Vaccine Trials that I helped to write. Greenwood says:

“Consideration of the ethics of a placebo-controlled trial after licensure of an effective vaccine will probably become a major issue in the next few years for development of malaria vaccines. If the partially effective RTS,S/AS01 malaria vaccine is licensed, then will all the novel malaria vaccines under development need to be compared with RTS,S/AS01, or will cheaper and faster placebo-controlled trials be allowed? Similar situations could arise with increasing frequency with the development of improved second-generation and third-generation vaccines against other infections. The Expert Panel has had a valuable role in raising further debate about some of the important ethics issues that trials of such vaccines will create.”

Read the full comment here and the paper on the WHO Report here.